SynCo Bio Partners Signs Agreement with a Japanese Pharmaceutical Company
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
SynCo Bio Partners B.V. has announced that it has expanded its business into a new geographical market, with the signing of a contract to manufacture a live biotherapeutic for an emerging Japanese pharmaceutical company.
The undisclosed company’s product is a live biotherapeutic based anticancer drug. The project will first involve a consultancy phase, during which SynCo will assist the client with in-house process development.
The developed process will then be transferred to SynCo’s Amsterdam facility and scaled-up, prior to GMP manufacture for Phase I clinical trials, including fermentation, formulation and aseptic filling.
“We are extremely pleased to be working our first Japanese partner” commented SynCo’s CEO, Mr. Pierre Warffemius ”this is an exciting project for a leading Japanese business and I look forward to the successful completion of GMP manufacture, in the field of live biotherapeutics. This contract represents SynCo’s entry into the growing Japanese biotherapeutics market and is reflective of our continuing success in a very competitive GMP contract manufacturing market.”
The undisclosed company’s product is a live biotherapeutic based anticancer drug. The project will first involve a consultancy phase, during which SynCo will assist the client with in-house process development.
The developed process will then be transferred to SynCo’s Amsterdam facility and scaled-up, prior to GMP manufacture for Phase I clinical trials, including fermentation, formulation and aseptic filling.
“We are extremely pleased to be working our first Japanese partner” commented SynCo’s CEO, Mr. Pierre Warffemius ”this is an exciting project for a leading Japanese business and I look forward to the successful completion of GMP manufacture, in the field of live biotherapeutics. This contract represents SynCo’s entry into the growing Japanese biotherapeutics market and is reflective of our continuing success in a very competitive GMP contract manufacturing market.”
